Our hypothesis was tested through different methodologies in a dual-BC-xenograft mouse model with human HER2-positive BC tumors, SKBr3 and JIMT1, the latter being resistant to trastuzumab due to MUC4 overexpression. The gene discussed is MUC4; the disease is breast cancer.